Which explains why FDA or CDRH pre-market and post-market reviews are difficult to perform on EHR software programs?

Which explains why FDA or CDRH pre-market and post-market reviews are difficult to perform on EHR software programs?

• A. The standard for "meaningful use" continues to change.
• B. Problems caused by related sources and configuration designs are not easily tested.
• C. Congressional debates concerning jurisdiction delays the reviewing process.
• D. Testing the software does not ensure proper use of the software.

Answer: (B)

Assessing EHR software for FDA/CDRH reviews is hard because the software does not operate in isolation. It relies on many related sources and integrations—interfaces with labs, imaging systems, payer feeds, pharmacy data, and other health IT components—along with varied configuration designs that clinics implement, such as user roles, workflows, security settings, and network infrastructure. This creates countless possible environments and data flows, so behavior can change depending on what other systems are connected, how data is mapped, and how the software is customized. Testing all those permutations before release and monitoring them after deployment is therefore extremely challenging, since issues may only appear under specific configurations or in combination with external data sources. The other choices miss this core point. The ongoing changes to meaningful use standards influence incentives and reporting criteria, not the inherent difficulty of evaluating software across diverse setups. Congressional jurisdiction debates affect regulatory timing, not the technical challenge of testing interconnected EHR systems. And while training and proper use are important, simply testing the software does not guarantee correct usage by all users; the regulatory testing concern here centers on how the software behaves within complex, variable environments rather than how users operate it.

Assessing EHR software for FDA/CDRH reviews is hard because the software does not operate in isolation. It relies on many related sources and integrations—interfaces with labs, imaging systems, payer feeds, pharmacy data, and other health IT components—along with varied configuration designs that clinics implement, such as user roles, workflows, security settings, and network infrastructure. This creates countless possible environments and data flows, so behavior can change depending on what other systems are connected, how data is mapped, and how the software is customized. Testing all those permutations before release and monitoring them after deployment is therefore extremely challenging, since issues may only appear under specific configurations or in combination with external data sources.

The other choices miss this core point. The ongoing changes to meaningful use standards influence incentives and reporting criteria, not the inherent difficulty of evaluating software across diverse setups. Congressional jurisdiction debates affect regulatory timing, not the technical challenge of testing interconnected EHR systems. And while training and proper use are important, simply testing the software does not guarantee correct usage by all users; the regulatory testing concern here centers on how the software behaves within complex, variable environments rather than how users operate it.